Cited by 3,063Cancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

Open access

Hellmann, Matthew D., Ciuleanu, Tudor-Eliade, Pluzanski, Adam, Lee, Jong Seok, Otterson, Gregory A., Audigier-Valette, Clarisse, Minenza, Elisa, Linardou, Helena, Burgers, Sjaak, Salman, Pamela, Borghaei, Hossein, Ramalingam, Suresh S., Brahmer, Julie, Reck, Martin, O’Byrne, Kenneth J., Geese, William J., Green, George, Chang, Han, Szustakowski, Joseph, Bhagavatheeswaran, Prabhu, Healey, Diane, Fu, Yali, Nathan, Faith, Paz-Ares, Luis·2018·New England Journal of Medicine

DOI 10.1056/nejmoa1801946PMC PMC7193684

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Nivolumab plus ipilimumab showed promising efficacy for the treatment of non-small-cell lung cancer (NSCLC) in a phase 1 trial, and tumor mutational burden has emerged as a potential biomarker of benefit. In this part of an open-label, multipart, phase 3 trial, we examined progression-free survival with nivolumab plus ipilimumab versus chemotherapy among patients with a high tumor mutational burden (≥10 mutations per megabase). METHODS: We enrolled patients with stage IV or recurrent NSCLC that was not previously treated with chemotherapy. Those with a level of tumor programmed death ligand 1 (PD-L1) expression of at least 1% were randomly assigned, in a 1:1:1 ratio, to receive nivolumab plus ipilimumab, nivolumab monotherapy, or chemotherapy; those with a tumor PD-L1 expression level of less than 1% were randomly assigned, in a 1:1:1 ratio, to receive nivolumab plus ipilimumab, nivolumab plus chemotherapy, or chemotherapy. Tumor mutational burden was determined by the FoundationOne CDx assay. RESULTS: Progression-free survival among patients with a high tumor mutational burden was significantly longer with nivolumab plus ipilimumab than with chemotherapy. The 1-year progression-free survival rate was 42.6% with nivolumab plus ipilimumab versus 13.2% with chemotherapy, and the median progression-free survival was 7.2 months (95% confidence interval [CI], 5.5 to 13.2) versus 5.5 months (95% CI, 4.4 to 5.8) (hazard ratio for disease progression or death, 0.58; 97.5% CI, 0.41 to 0.81; P<0.001). The objective response rate was 45.3% with nivolumab plus ipilimumab and 26.9% with chemotherapy. The benefit of nivolumab plus ipilimumab over chemotherapy was broadly consistent within subgroups, including patients with a PD-L1 expression level of at least 1% and those with a level of less than 1%. The rate of grade 3 or 4 treatment-related adverse events was 31.2% with nivolumab plus ipilimumab and 36.1% with chemotherapy. ical; CheckMate 227 ClinicalTrials.gov number, NCT02477826 .). CONCLUSIONS: Progression-free survival was significantly longer with first-line nivolumab plus ipilimumab than with chemotherapy among patients with NSCLC and a high tumor mutational burden, irrespective of PD-L1 expression level. The results validate the benefit of nivolumab plus ipilimumab in NSCLC and the role of tumor mutational burden as a biomarker for patient selection. (Funded by Bristol-Myers Squibb and Ono Pharmaceut

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1801946

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Self-citation
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citation
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Self-citation
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519
Tumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839

Show all 22 references

Sorted by citations

Items 501–600 of 1,002

Molecular Pathology of Lung CancerPreprint
Saller, J. J., & Boyle, T. A. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a037812 · Cited by 83
Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature
Sabbatino, F., Marra, A., Liguori, L., Scognamiglio, G., Fusciello, C., Botti, G., Ferrone, S., & Pepe, S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0439-2 · Cited by 71
Anti–CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control
Sanseviero, E., O’Brien, E. M., Karras, J. R., Shabaneh, T. B., Aksoy, B. A., Xu, W., Zheng, C., Yin, X., Xu, X., Karakousis, G. C., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0386 · Cited by 70
Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancers
Mody, K., Starr, J. S., Saul, M. E., Poorman, K. A., Weinberg, B. A., Salem, M. E., Vanderwalde, A. M., & Shields, A. F. (2019) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2019.08.08 · Cited by 70
Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy
Schetters, S. T. T., Rodríguez, E., Kruijssen, L. J. W., Crommentuijn, M. H. W., Boon, L., den Bossche, J. V., den Haan, J. M. M., & van Kooyk, Y. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000588 · Cited by 79
Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma
Park, C., Na, K. J., Choi, H., Ock, C., Ha, S., Kim, M., Park, S., Keam, B., Kim, T. M., Paeng, J. C., et al. (2020) · Theranostics · doi:10.7150/thno.50283 · Cited by 71
The impact of ARID1A mutation on molecular characteristics in colorectal cancer
Tokunaga, R., Xiu, J., Goldberg, R. M., Philip, P. A., Seeber, A., Battaglin, F., Arai, H., Lo, J. H., Naseem, M., Puccini, A., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.09.006 · Cited by 71
The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors
Wu, Z., Cui, P., Tao, H., Zhang, S., Ma, J., Liu, Z., Wang, J., Qian, Y., Chen, S., Huang, Z., et al. (2021) · Clinical Medicine Insights Oncology · doi:10.1177/1179554921996288 · Cited by 72
High concordance of actionable genomic alterations identified between circulating tumor DNA–based and tissue‐based next‐generation sequencing testing in advanced non–small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program
Park, S., Olsen, S., Ku, B. M., Lee, M., Jung, H. A., Sun, J., Lee, S., Ahn, J. S., Park, K., Choi, Y., et al. (2021) · Cancer · doi:10.1002/cncr.33571 · Cited by 71
Three-Year Follow-Up of Neoadjuvant Programmed Cell Death Protein-1 Inhibitor (Sintilimab) in NSCLC
Zhang, F., Guo, W., Zhou, B., Wang, S., Li, N., Qiu, B., Lv, F., Zhao, L., Li, J., Shao, K., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.04.012 · Cited by 70
Update on prognostic and predictive biomarkers of breast cancer
Hou, Y., Peng, Y. S., & Li, Z. (2022) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2022.06.015 · Cited by 72
The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression
Kim, C. M., Lee, J. B., Shin, S. J., Ahn, J. B., Lee, M., & Kim, H. S. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100577 · Cited by 77
Self-citation
Computational immunogenomic approaches to predict response to cancer immunotherapies
Addala, V., Newell, F., Pearson, J. V., Redwood, A., Robinson, B. W. S., Creaney, J., & Waddell, N. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00830-6 · Cited by 79
Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi)
Dudnik, E., Bshara, E., Grubstein, A., Fridel, L., Shochat, T., Roisman, L. C., Ilouze, M., Rozenblum, A. B., Geva, S., Zer, A., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.07.044 · Cited by 71
Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?
Lemiale, V., Meert, A., Vincent, F., Darmon, M., Bauer, P. R., de Louw, A. V., & Azoulay, É. (2019) · Annals of Intensive Care · doi:10.1186/s13613-019-0487-x · Cited by 73
Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy
Chrétien, S., Zerdes, I., Bergh, J. C. S., Matikas, A., & Foukakis, T. (2019) · Cancers · doi:10.3390/cancers11050628 · Cited by 71
Immune Checkpoint Inhibitor–Mediated Diarrhea and Colitis: A Clinical Review
Gong, Z., & Wang, Y. (2020) · JCO Oncology Practice · doi:10.1200/op.20.00002 · Cited by 71
Comprehensive molecular analyses of a TNF family-based signature with regard to prognosis, immune features, and biomarkers for immunotherapy in lung adenocarcinoma
Zhang, C., Zhang, G., Sun, N., Zhang, Z., Zhang, Z., Luo, Y., Che, Y., Xue, Q., & He, J. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102959 · Cited by 66
The Evolution of STING Signaling and Its Involvement in Cancer
Vashi, N., & Bakhoum, S. F. W. (2021) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2020.12.010 · Cited by 72
Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody–Drug Conjugate and Immune Checkpoint Blockade
Boshuizen, J., Pencheva, N., Krijgsman, O., Altimari, D. M. D., Castro, P. G., de Bruijn, B., Ligtenberg, M. A., den Heuvel, E. G.-V., Vredevoogd, D. W., Song, J., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-0434 · Cited by 73
Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma
Haymaker, C., Johnson, D. H., Murthy, R., Bentebibel, S.-E., Uemura, M. I., Hudgens, C. W., Safa, H., James, M. L., Andtbacka, R. H. I., Johnson, D. B., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1546 · Cited by 70
Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer
Wang, X., Ricciuti, B., Alessi, J. V., Nguyen, T. T., Awad, M. M., Lin, X., Johnson, B. E., & Christiani, D. C. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab116 · Cited by 72
Neoantigen Identification and Response to Adoptive Cell Transfer in Anti–PD-1 Naïve and Experienced Patients with Metastatic Melanoma
Levi, S. T., Copeland, A. R., Nah, S., Crystal, J. S., Ivey, G. D., Lalani, A., Jafferji, M. S., White, B. S., Parikh, N. B., Leko, V., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-4499 · Cited by 72
Tumor aneuploidy predicts survival following immunotherapy across multiple cancers
Spurr, L. F., Weichselbaum, R. R., & Pitroda, S. P. (2022) · Nature Genetics · doi:10.1038/s41588-022-01235-4 · Cited by 72
Spatial genomic, biochemical and cellular mechanisms underlying meningioma heterogeneity and evolution
Lucas, C. G., Mirchia, K., Seo, K., Najem, H., Chen, W., Zakimi, N., Foster, K. J., Eaton, C. D., Cady, M. A., Choudhury, A., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01747-1 · Cited by 72
Measuring tumor mutation burden in non-small cell lung cancer: Tissue versus liquid biopsy
Fenizia, F., Pasquale, R., Roma, C., Bergantino, F., Iannaccone, A., & Normanno, N. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.09.23 · Cited by 69
A nomogram-based immunoprofile predicts overall survival for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy
Duan, J., Xie, Y., Qu, L., Wang, L., Zhou, S., Wang, Y., Fan, Z., Yang, S., & Jiao, S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0418-7 · Cited by 71
Role of DNA repair defects in predicting immunotherapy response
Zhang, J., Shih, D. J. H., & Lin, S. (2020) · Biomarker Research · doi:10.1186/s40364-020-00202-7 · Cited by 70
Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis
Gudd, C. L. C., Au, L., Triantafyllou, E., Shum, B., Liu, T., Nathwani, R., Kumar, N., Mukherjee, S. K., Dhar, A., Woollard, K. J., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.02.008 · Cited by 69
Imaging Biomarkers to Predict and Evaluate the Effectiveness of Immunotherapy in Advanced Non-Small-Cell Lung Cancer
Liu, Y., Wu, M., Zhang, Y., Luo, Y., He, S., Wang, Y., Chen, F., Liu, Y., Yang, Q., Li, Y., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.657615 · Cited by 70
Prognostic and Predictive Factors in Advanced Head and Neck Squamous Cell Carcinoma
Magnes, T., Wagner, S. M., Kiem, D., Weiß, L., Rinnerthaler, G., Greil, R., & Melchardt, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094981 · Cited by 74
Liquid biopsy on the horizon in immunotherapy of non-small cell lung cancer: current status, challenges, and perspectives
Yang, Y., Liu, H., Chen, Y., Xiao, N., Zheng, Z., Liu, H., & Wan, J. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05757-5 · Cited by 71
A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer
Nadal, E., Saleh, M. N., Ponce-Aix, S., Ochoa-de-Olza, M., Patel, S. P., Antonia, S. J., Zhao, Y., Gueorguieva, I., Man, M. Z., Estrem, S. T., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-11153-1 · Cited by 70
Beyond PD-L1 Markers for Lung Cancer Immunotherapy
Wojas‐Krawczyk, K., Kalinka‐Warzocha, E., Grenda, A., Krawczyk, P. A., & Milanowski, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081915 · Cited by 71
Radiomics-based prediction model for outcomes of PD-1/PD-L1 immunotherapy in metastatic urothelial carcinoma
Park, K., Lee, J.-L., Yoon, S., Heo, C., Park, B., & Kim, J. K. (2020) · European Radiology · doi:10.1007/s00330-020-06847-0 · Cited by 55
Self-citation
Immunotherapy Treatment for Triple Negative Breast Cancer
Berger, E. R., Park, T. S., Saridakis, A., Golshan, M. A., Greenup, R. A., & Ahuja, N. (2021) · Pharmaceuticals · doi:10.3390/ph14080763 · Cited by 72
An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer
Ahmadzada, T., Kao, S., Reid, G., Boyer, M. J., Mahar, A. M., & Cooper, W. A. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7060153 · Cited by 68
NCCN Guidelines Updates: New Immunotherapy Strategies for Improving Outcomes in Non-Small Cell Lung Cancer.
Gubens, M. A., & Davies, M. J. (2019) · PubMed · doi:10.6004/jnccn.2019.5005 · Cited by 68
Immune-related adverse events are linked with improved progression-free survival in patients receiving anti-PD-1/PD-L1 therapy
Shafqat, H., Gourdin, T. S., & Sion, A. M. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.07.003 · Cited by 68
Racial differences in characteristics and prognoses between Asian and white patients with nonsmall cell lung cancer receiving atezolizumab: An ancillary analysis of the POPLAR and OAK studies
Qian, J., Nie, W., Lü, J., Zhang, L., Zhang, Y., Zhang, B., Wang, S., Hu, M., Xu, J., Lou, Y., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32717 · Cited by 67
Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation?
Masterson, L. M., Howard, J. E. F., Cruz, J. L. G., Jackson, C. C., Barnett, C. M. E., Overton, L., Liu, H. Y.-H., Ladwa, R., Simpson, F., McGrath, M., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.32869 · Cited by 67
Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges
Nimmagadda, S. (2020) · Cancers · doi:10.3390/cancers12113173 · Cited by 68
Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond
Uruga, H., & Mino-Kenudson, M. A. (2021) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-021-03030-8 · Cited by 69
Immunotherapy in non-small cell lung cancer: update and new insights
Mielgo-Rubio, X., Uribelarrea, E. A., Cortés, L. Q., & Moyano, M. S. (2021) · Journal of Clinical and Translational Research · doi:10.18053/jctres.07.202101.001 · Cited by 65
Gene code CD274/PD-L1 : from molecular basis toward cancer immunotherapy
Fabrizio, F. P., Trombetta, D., Rossi, A., Sparaneo, A., Castellana, S., & Muscarella, L. A. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918815598 · Cited by 67
A Novel Paradigm Between Leukocytosis, G-CSF Secretion, Neutrophil-to-Lymphocyte Ratio, Myeloid-Derived Suppressor Cells, and Prognosis in Non-small Cell Lung Cancer
Tavakkoli, M., Wilkins, C. R., Mones, J. V., & Mauro, M. J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00295 · Cited by 66
Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer
Lü, Z., Chen, H., Li, S., Gong, J., Li, J., Zou, J., Wu, L., Yu, J., Han, W., Sun, H., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000374 · Cited by 65
Recent advances in preclinical models for lung squamous cell carcinoma
Pan, Y., Han, H., Labbe, K. E., Zhang, H., & Wong, K. (2021) · Oncogene · doi:10.1038/s41388-021-01723-7 · Cited by 68
AR Splicing Variants and Resistance to AR Targeting Agents
Kanayama, M., Lu, C., Luo, J., & Antonarakis, E. S. (2021) · Cancers · doi:10.3390/cancers13112563 · Cited by 68
Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment
Wang, M., Liu, Y., Cheng, Y., Wei, Y., & Wei, X. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.12.002 · Cited by 66
The Promise of Digital Biopsy for the Prediction of Tumor Molecular Features and Clinical Outcomes Associated With Immunotherapy
Banna, G. L., Olivier, T., Rundo, F., Malapelle, U., Fraggetta, F., Libra, M., & Addeo, A. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00172 · Cited by 66
Association Between Tumor Mutation Burden (TMB) and Outcomes of Cancer Patients Treated With PD-1/PD-L1 Inhibitions: A Meta-Analysis
Zhu, J.-X., Zhang, T., Li, J., Lin, J., Liang, W., Huang, W., Wan, N., & Jiang, J. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00673 · Cited by 65
Immune checkpoint inhibitors for head and neck squamous cell carcinoma: Current landscape and future directions
Kao, H., & Lou, P. (2019) · Head & Neck · doi:10.1002/hed.25930 · Cited by 66
High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis
Jung, J., Heo, Y. J., & Park, S. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006454 · Cited by 65
The Use of Microfluidic Technology for Cancer Applications and Liquid Biopsy
Kulasinghe, A., Wu, H., Punyadeera, C., & Warkiani, M. E. (2018) · Micromachines · doi:10.3390/mi9080397 · Cited by 67
Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives
Caparica, R., Lambertini, M., Ponde, N. F., Fumagalli, D., de Azambuja, E., & Piccart, M. J. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919827714 · Cited by 66
Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade
Huemer, F., Lang, D., Westphal, T., Gampenrieder, S. P., Hutarew, G., Weiß, L., Hackl, H., Lamprecht, B., Rinnerthaler, G., & Greil, R. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8071014 · Cited by 68
Relationship Between Progression‐Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD‐1/PD‐L1 Immune Checkpoint Blockade: A Meta‐Analysis
Ye, J., Ji, X., Dennis, P. A., Abdullah, H. A., & Mukhopadhyay, P. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1956 · Cited by 69
Dynamic Changes of Circulating Tumor DNA Predict Clinical Outcome in Patients With Advanced Non–Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
Weber, S., van der Leest, P., Donker, H. C., Schlange, T., Timens, W., Tamminga, M., Hasenleithner, S. O., Graf, R., Moser, T., Spiegl, B., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00182 · Cited by 64
Immuno-oncology trends: preclinical models, biomarkers, and clinical development
Franklin, M. R., Platero, S. J., Saini, K. S., Curigliano, G., & Anderson, S. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003231 · Cited by 69
Circulating free tumor DNA in non-small cell lung cancer (NSCLC): clinical application and future perspectives
Herbreteau, G., Vallée, A., Charpentier, S., Normanno, N., Hofman, P. M., & Denis, M. G. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.12.18 · Cited by 65
Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non–Small Cell Lung Cancer in the Context of the US Health Care System
Criss, S. D., Mooradian, M. J., Sheehan, D. F., Zubiri, L., Lumish, M. A., Gainor, J. F., Reynolds, K. L., & Kong, C. Y. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5449 · Cited by 64
The appropriate frequency and function of decidual Tim-3+CTLA-4+CD8+ T cells are important in maintaining normal pregnancy
Wang, S., Sun, F., Li, M., Qian, J., Chen, C., Wang, M., Zang, X., Li, D., Yu, M., & Du, M. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1642-x · Cited by 64
Neoadjuvant chemoradiation alters biomarkers of anticancer immunotherapy responses in locally advanced rectal cancer
Seo, I., Lee, H. W., Byun, S. J., Park, J. Y., Min, H., Lee, S. H., Lee, J., Kim, S., & Bae, S. U. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001610 · Cited by 65
Self-citation
Artificial intelligence-based biomarkers for treatment decisions in oncology
Ligero, M., Nahhas, O. S. M. E., Aldea, M. D., & Kather, J. N. (2025) · Trends in cancer · doi:10.1016/j.trecan.2024.12.001 · Cited by 74
The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung Cancer
Kaderbhaï, C., Tharin, Z., & Ghiringhelli, F. (2019) · Cancers · doi:10.3390/cancers11020201 · Cited by 63
Prognostic Factors and Biomarkers of Responses to Immune Checkpoint Inhibitors in Lung Cancer
Bianco, A., Perrotta, F., Barra, G., Malapelle, U., Rocco, D., & Palma, R. D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194931 · Cited by 65
Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)
Ruíz-Patiño, A., Arrieta, O. G., Cardona, A. F., Martin, C. M., Raez, L. E., Zatarain-Barrón, Z. L., Barrón, F., Ricaurte, L., Bravo-Garzón, M. A., Mas, L. A., et al. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13272 · Cited by 64
DNAH10 mutation correlates with cisplatin sensitivity and tumor mutation burden in small-cell lung cancer
Li, M., Lin, A., Luo, P., Shen, W., Xiao, D., Gou, L., Zhang, J., & Guo, L. (2020) · Aging · doi:10.18632/aging.102683 · Cited by 62
The Inflammatory Milieu of Adamantinomatous Craniopharyngioma and Its Implications for Treatment
Whelan, R., Prince, E. W., Gilani, A., & Hankinson, T. C. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020519 · Cited by 63
Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient
Rossi, G., Russo, A., Tagliamento, M., Tuzi, A., Nigro, O., Vallome, G., Sini, C., Grassi, M., Bello, M. G. D., Coco, S., et al. (2020) · Cancers · doi:10.3390/cancers12051125 · Cited by 61
Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data
Dudnik, E., Moskovitz, M. T., Rottenberg, Y., Lobachov, A., Mandelboim, R., Shochat, T., Urban, D., Wollner, M., Nechushtan, H., Rotem, O., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2020.1865653 · Cited by 62
NOTCH3 is a Prognostic Factor and Is Correlated With Immune Tolerance in Gastric Cancer
Cui, Y., Li, Q., Li, W., Wang, Y., Lv, F., Shi, X., Tang, Z., Shen, Z., Hou, Y., Zhang, H., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.574937 · Cited by 62
Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration
Zhou, Y., Medik, Y. B., Patel, B., Zamler, D. B., Chen, S., Chapman, T., Schneider, S. M., Park, E. M., Babcock, R. L., Chrisikos, T. T., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20221333 · Cited by 63
Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors
Manca, P., Corti, F., Intini, R., Mazzoli, G., Miceli, R., Germani, M. M., Bergamo, F., Ambrosini, M., Cristarella, E., Cerantola, R., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.03.029 · Cited by 69
Recent success and limitations of immune checkpoint inhibitors for cancer: A lesson from melanoma
Ottaviano, M., De Placido, S., & Ascierto, P. A. (2019) · Virchows Archiv · doi:10.1007/s00428-019-02538-4 · Cited by 57
A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer
Jafarnejad, M., Gong, C., Gabrielson, E., Bartelink, I. H., Vicini, P., Wang, B., Narwal, R., Roskos, L. K., & Popel, A. S. (2019) · The AAPS Journal · doi:10.1208/s12248-019-0350-x · Cited by 60
Preanalytic Variables and Tissue Stewardship for Reliable Next-Generation Sequencing (NGS) Clinical Analysis
Ascierto, P. A., Bifulco, C. B., Palmieri, G., Peters, S., & Sidiropoulos, N. (2019) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2019.05.004 · Cited by 65
P5 eHealth: An Agenda for the Health Technologies of the Future
Pravettoni, G., & Triberti, S. (2019) · Springer eBooks · doi:10.1007/978-3-030-27994-3 · Cited by 63
Epigenetic landscape of small cell lung cancer: small image of a giant recalcitrant disease
Κhan, P., Siddiqui, J. A., Maurya, S. K., Lakshmanan, I., Jain, M., Ganti, A. K., Salgia, R., Batra, S. K., & Nasser, M. W. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.11.006 · Cited by 64
Advances in Small-Cell Lung Cancer (SCLC) Translational ResearchPreprint
Drapkin, B. J., & Rudin, C. M. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a038240 · Cited by 63
Tobacco exposure and immunotherapy response in PD-L1 positive lung cancer patients
Li, J. J. N., Karim, K., Sung, M., Le, L. W., Lau, S. C. M., Sacher, A. G., & Leighl, N. B. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.10.023 · Cited by 64
Intravenous injection of the oncolytic virus M1 awakens antitumor T cells and overcomes resistance to checkpoint blockade
Liu, Y., Cai, J., Liu, W., Lin, Y., Guo, L., Liu, X., Qin, Z., Xu, C., Zhang, Y., Su, X., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03285-0 · Cited by 61
Imaging of Precision Therapy for Lung Cancer: Current State of the Art
Park, H., Sholl, L. M., Hatabu, H., Awad, M. M., & Nishino, M. (2019) · Radiology · doi:10.1148/radiol.2019190173 · Cited by 61
Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?
Cantini, L., Hassan, R., Sterman, D. H., & Aerts, J. G. J. V. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00343 · Cited by 60
Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study
Bai, X., Wu, D., Ma, S.-C., Wang, J., Tang, X.-R., Kang, S., Fu, Q. J., Cao, C., Luo, H.-S., Chen, Y., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000381 · Cited by 60
Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions
Choudhury, N. J., Schoenfeld, A. J., Flynn, J. R., Falcon, C. J., Rizvi, H. A., Rudin, C. M., Kris, M. G., Arcila, M. E., Heller, G., Yu, H. A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4650 · Cited by 60
A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer
Pacheco, J. M., Camidge, D. R., Doebele, R. C., & Schenk, E. L. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00195 · Cited by 60
Kiss and Run: Promoting Effective and Targeted Cellular Uptake of a Drug Delivery Vehicle Composed of an Integrin-Targeting Diketopiperazine Peptidomimetic and a Cell-Penetrating Peptide
Feni, L., Parente, S., Robert, C., Gazzola, S., Arosio, D., Piarulli, U., & Neundorf, I. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00292 · Cited by 62
Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater
She, L., Hu, H., Liao, M., Xia, X., Shi, Y., Yao, L., Ding, D., Zhu, Y., Zeng, S., Shen, L., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.10.017 · Cited by 60
First-Line Therapies for Metastatic Lung Adenocarcinoma Without a Driver Mutation
Bodor, J. N., Kasireddy, V., & Borghaei, H. (2018) · Journal of Oncology Practice · doi:10.1200/jop.18.00250 · Cited by 58
Self-citation
Current status and development of anti-PD-1/PD-L1 immunotherapy for lung cancer
Wang, L., Ma, Q., Yao, R., & Liu, J. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.106088 · Cited by 60
Comparative analysis of machine learning approaches to classify tumor mutation burden in lung adenocarcinoma using histopathology images
Sadhwani, A., Chang, H.-W., Behrooz, A., Brown, T., Flament-Auvigne, I., Patel, H., Findlater, R., Velez, V., Tan, F. E., Tekiela, K., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-95747-4 · Cited by 63
Self-citation
The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer
Pan, Y., Fu, Y., Zeng, Y., Liu, X., Peng, Y., Hu, C., Deng, C., Qiu, Z., Zou, J. P., Liu, Y., et al. (2022) · Biomarker Research · doi:10.1186/s40364-022-00355-7 · Cited by 57
Self-citation
Discontinuation due to immune‐related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non‐small cell lung cancer
Komiya, K., Nakamura, T., Abe, T., Ogusu, S., Nakashima, C., Takahashi, K., Kimura, S. H., & Sueoka‐Aragane, N. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13149 · Cited by 59
How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?
Denis, M., Duruisseaux, M., Brevet, M., & Dumontet, C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00492 · Cited by 59
Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab
Simonaggio, A., Elaidi, R., Fournier, L. S., Fabre, E., Ferrari, V., Borchiellini, D., Thouvenin, J., Barthélémy, P., Thibault, C., Tartour, É., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02637-1 · Cited by 62
Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer
Aso, M., Toi, Y., Sugisaka, J., Aiba, T., Kawana, S., Saito, R., Ogasawara, T., Tsurumi, K., Ono, K., Shimizu, H., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0550 · Cited by 57
Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment
Krieger, T., Pearson, I. V., Bell, J. A., Doherty, J. P., & Robbins, P. B. (2020) · Diagnostic Pathology · doi:10.1186/s13000-020-0927-9 · Cited by 61
The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China
Chen, Y., Wang, Y., Luo, H., Meng, X., Zhu, W., Wang, D., Zeng, H., & Zhang, H. (2020) · Experimental Hematology and Oncology · doi:10.1186/s40164-020-00173-3 · Cited by 58

Authors: Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., Borghaei, H., Ramalingam, S. S., Brahmer, J., Reck, M., O’Byrne, K. J., Geese, W. J., Green, G., Chang, H., Szustakowski, J., Bhagavatheeswaran, P., Healey, D., Fu, Y., Nathan, F., & Paz-Ares, L.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
From Memorial Sloan Kettering Cancer Center Hospital, New York (M.D.H.); Prof. Dr. Ion Chiricuta Institute of Oncology and Universitatea de Medicina si Farmacie Iuliu Hatieganu, Cluj-Napoca, Romania (T.-E.C.); Centrum Onkologii–Instytut im. Marii Sklodowskiej-Curie, Warsaw, Poland (A.P.); Seoul National University Bundang Hospital, Seoul, South Korea (J.S.L.); Ohio State University, Columbus (G.A.O.); Hôpital Sainte Musse, Toulon, France (C.A.-V.); Ospedale Santa Maria della Misericordia, Perugia,...
Fox Chase Cancer Center (US)
ORCID: Hellmann, Matthew D.
Ciuleanu, Tudor-Eliade
Lee, Jong Seok
Otterson, Gregory A.
Audigier-Valette, Clarisse
Linardou, Helena
Burgers, Sjaak
Salman, Pamela
Borghaei, Hossein
Ramalingam, Suresh S.
Brahmer, Julie
Reck, Martin
Geese, William J.
Green, George
Szustakowski, Joseph
Fu, Yali
Paz-Ares, Luis
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2018-05-31
Volume: 378
Issue: 22
Pages: 2093-2104
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1801946
PMC: PMC7193684
OpenAlex: W2797675588
Cited by: 3,063
References: 22
Citations by year: 2026: 100 · 2025: 184 · 2024: 222 · 2023: 289 · 2022: 419 · 2021: 499 · 2020: 559 · 2019: 542 · 2018: 247
FWCI: 174.31
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: Bristol-Myers Squibb, Inc.
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: nivolumab, ipilimumab, non-small cell lung cancer, tumor mutational burden, PD-L1 expression, immune checkpoint inhibitors, progression-free survival, chemotherapy comparison, stage IV lung cancer, treatment-related adverse events, treatment response biomarkers, objective response rate, immunotherapy biomarkers, safety and tolerability
MeSH terms: Antineoplastic Agents, Immunological, Ipilimumab, Nivolumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Neoplasm Staging, Biomarkers, Tumor, Disease-Free Survival, Kaplan-Meier Estimate, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks